AGA Family of Websites:
AGA Journals
AGA Journals
AGA University
AGA University
AGA University
AGA Research Foundation
AGA University
AGA Community
AGA University
AGA Job Board
Female medicine doctor hand holding silver pen looking in clipboard pad closeup. Ward round, patient visit check, 911, medical calculation and statistics concept. Physician ready to examine patient
November 6, 2019

Explore challenging cases in IBD management

Learn how to optimize IBD care through challenging cases presented by esteemed faculty experts.
Share on facebook
Share on twitter
Share on linkedin
Share on email

Today’s complex clinical care landscape requires equally challenging case-based discussions to foster collaboration and innovative treatment approaches.

Founded upon the AGA Clinical Care Pathways and evidence-based literature, the AGA University course, Optimizing Management in IBD: Challenging Cases, is a 45-minute program designed to test — and sharpen — clinicians’ knowledge of best practice surrounding the treatment of patients with inflammatory bowel disease (IBD).

Case vignettes of patients with ulcerative colitis and Crohn’s disease are presented with accompanying challenge questions, in addition to feedback on medical management from the following esteemed faculty: Gil Y. Melmed, MD, MS (chair), Adam S. Cheifetz, MD, and Gary R. Lichtenstein, MD, FACP, FACG, AGAF.

Complete this free course by Wednesday, Dec. 25, to receive 0.75 AMA PRA Category 1 Credit(s)™ and be able to:

  • 1. Differentiate between current, novel and future IBD therapies based on their efficacy and safety data.
  • 2. Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse and minimize toxicity.
  • 3. Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD.
  • 4. Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement and shared decision making.

This activity is supported by independent educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Salix Pharmaceuticals.

Your hub for GI education is
AGA University
Discussion Icon

Discuss this news

Share this article in the AGA Community, your member-only platform for sharing your thoughts and ideas with your colleagues.

Not a member? Join AGA.

By using this site, you agree to our updated Privacy Policy.